News

Company appoints Dr Russell Greig as chairman of the supervisory board.

NCGR achieves Certified Service Provider status for target enrichment system for next-generation sequencing.

Acquisition addresses a new and rapidly growing area of healthcare with technology and clinical expertise to manage adult stem cells and cord blood in the treatment of cancer.

The company announced that the first patient in the Phase III clinical study of its lead cancer drug was randomized on Dec 30, 2011 and has now received their first cycle of treatment.

The goal of the Phase I clinical trial is to establish the safety and immune activity of therapeutic cancer vaccine DPX-Survivac in patients with ovarian cancer.

The company achieved positive preliminary results from its ongoing clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia. ALN-PCS demonstrated statistically significant RNAi silencing of PCSK9 of up to 66% and reductions of up to over 50% in levels of low-density lipoprotein cholesterol (LDL-C), a clinically validated endpoint.

Company announces payments completion for clinical trial of UMK-121 in patients with ESLD.

A new genetics educational program will provide social and behavioral scientists with sufficient genetics background to allow them to engage effectively in interdisciplinary research with genetics researchers.

LODOTRA NDA submission was primarily based on results from the CAPRA-2 trial.

Metabolon, Inc. announces the grant of EP Patent 2,089,539B entitled, “Biomarkers Related to Metabolic Age and Methods Using the Same.”